Fusion Antibodies plc – LSE:FAB.L
Fusion Antibodies stock price today
Fusion Antibodies stock price monthly change
Fusion Antibodies stock price quarterly change
Fusion Antibodies stock price yearly change
Fusion Antibodies key metrics
Market Cap | 6.54M |
Enterprise value | 849.64M |
P/E | -5.5 |
EV/Sales | 218.13 |
EV/EBITDA | -1971.33 |
Price/Sales | 2.18 |
Price/Book | 3.30 |
PEG ratio | -0.09 |
EPS | -0.14 |
Revenue | 4.62M |
EBITDA | -3.97M |
Income | -4.26M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -17.89% |
Oper. margin | -27.19% |
Gross margin | 45.49% |
EBIT margin | -27.19% |
EBITDA margin | -86.05% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeFusion Antibodies stock price history
Fusion Antibodies stock forecast
Fusion Antibodies financial statements
| Dec 2021 | 1.17M | -308K | -26.12% |
|---|---|---|---|
| Sep 2022 | 1.86M | -1.11M | -59.9% |
| Mar 2023 | 1.03M | -1.48M | -142.58% |
| Sep 2023 | 541K | -1.35M | -250.83% |
| Jun 2022 | 3982000 | 1.14M | 28.63% |
|---|---|---|---|
| Sep 2022 | 3982000 | 1.41M | 35.41% |
| Dec 2022 | 2061999 | 879K | 42.63% |
| Sep 2023 | 2057999 | 604K | 29.35% |
| Sep 2021 | -507K | -191K | -1K |
|---|---|---|---|
| Sep 2022 | -760K | -358K | 267K |
| Mar 2023 | -995K | 244K | -260K |
| Sep 2023 | -1.35M | 2K | 1.64M |
Fusion Antibodies alternative data
| Aug 2023 | 55 |
|---|---|
| Sep 2023 | 55 |
| Oct 2023 | 55 |
| Nov 2023 | 48 |
| Dec 2023 | 48 |
| Jan 2024 | 48 |
| Feb 2024 | 48 |
| Mar 2024 | 48 |
| Apr 2024 | 48 |
| May 2024 | 48 |
| Jun 2024 | 48 |
| Jul 2024 | 48 |
Fusion Antibodies other data
| Insider | Compensation |
|---|---|
Dr. Paul Gerard Kerr (1973) Consultant | $180,380 |
Dr. Richard Anthony Jones Ph.D. (1973) Chief Executive Officer & Director | $148,510 |
Dr. Richard John Buick Ph.D. (1976) Chief Scientific Officer & Director | $131,000 |
Mr. James Fair (1966) Chief Financial Officer, Company Sec. & Director | $125,000 |
-
What's the price of Fusion Antibodies stock today?
One share of Fusion Antibodies stock can currently be purchased for approximately $110.
-
When is Fusion Antibodies's next earnings date?
Unfortunately, Fusion Antibodies's (FAB.L) next earnings date is currently unknown.
-
Does Fusion Antibodies pay dividends?
No, Fusion Antibodies does not pay dividends.
-
How much money does Fusion Antibodies make?
Fusion Antibodies has a market capitalization of 6.54M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 76.33% to 1.14M US dollars.
-
What is Fusion Antibodies's stock symbol?
Fusion Antibodies plc is traded on the LSE under the ticker symbol "FAB.L".
-
What is Fusion Antibodies's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Fusion Antibodies?
Shares of Fusion Antibodies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Fusion Antibodies's key executives?
Fusion Antibodies's management team includes the following people:
- Dr. Paul Gerard Kerr Consultant(age: 52, pay: $180,380)
- Dr. Richard Anthony Jones Ph.D. Chief Executive Officer & Director(age: 52, pay: $148,510)
- Dr. Richard John Buick Ph.D. Chief Scientific Officer & Director(age: 49, pay: $131,000)
- Mr. James Fair Chief Financial Officer, Company Sec. & Director(age: 59, pay: $125,000)
-
How many employees does Fusion Antibodies have?
As Jul 2024, Fusion Antibodies employs 48 workers.
-
When Fusion Antibodies went public?
Fusion Antibodies plc is publicly traded company for more then 7 years since IPO on 18 Dec 2017.
-
What is Fusion Antibodies's official website?
The official website for Fusion Antibodies is fusionantibodies.com.
-
How can i contact Fusion Antibodies?
Fusion Antibodies can be reached via phone at +44 28 9043 2800.
Fusion Antibodies company profile:
Fusion Antibodies plc
fusionantibodies.comLSE
27
Biotechnology
Healthcare
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Belfast, BT17 0QL
:
ISIN: GB00BDQZGK16
CUSIP: G3708Z104
